Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15198
UPID:
SMAD9_HUMAN
Alternative names:
Madh6; SMAD family member 9
Alternative UPACC:
O15198; A2A2Y6; O14989; Q5TBA1
Background:
Mothers against decapentaplegic homolog 9 (SMAD9), also known as Madh6, is a transcriptional modulator activated by BMP type 1 receptor kinase. As a receptor-regulated SMAD (R-SMAD), SMAD9 plays a pivotal role in cellular processes regulated by the BMP pathway, which is crucial for development and tissue homeostasis.
Therapeutic significance:
SMAD9's involvement in Pulmonary hypertension, primary, 2, a rare disorder characterized by plexiform lesions in pulmonary arterioles, underscores its potential as a therapeutic target. Understanding the role of SMAD9 could open doors to novel strategies for managing this life-threatening condition.